Founded in 2005 and headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC specializes in the engineering of novel biologics to treat anemias, cancers and their debilitating comorbidities by leveraging the multi-faceted core attributes of PEGylation technology. The company’s lead product, SANGUINATEā„¢, focuses on treating disorders caused by ischemia, hypoxia and/or hemolysis.Ā  It is in clinical testing for hypoxia and anemia-related conditions with broader applications anticipated in the future.

This website uses cookies to ensure you get the best experience on our website.